Merus N.V. - Common Shares (MRUS)
55.14
+13.54 (32.55%)
NASDAQ · Last Trade: May 24th, 2:43 PM EDT
Detailed Quote
Previous Close | 41.60 |
---|---|
Open | 50.20 |
Bid | 54.57 |
Ask | 54.70 |
Day's Range | 49.00 - 57.45 |
52 Week Range | 33.19 - 61.61 |
Volume | 7,883,816 |
Market Cap | 2.57B |
PE Ratio (TTM) | -13.51 |
EPS (TTM) | -4.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,253,200 |
Chart
About Merus N.V. - Common Shares (MRUS)
Merus N.V. is a biotechnology company that specializes in the development of innovative therapeutic solutions, particularly focused on creating bispecific antibodies for cancer treatment. By leveraging its proprietary technology platforms, Merus aims to enhance the effectiveness of cancer therapies by targeting multiple pathways simultaneously, ultimately improving patient outcomes. The company's research and development efforts are directed towards various oncology indications, with a commitment to advancing clinical trials and bringing new treatments to market that can address unmet medical needs in the fight against cancer. Read More
News & Press Releases
Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for head and neck cancer.
Via Benzinga · May 23, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · May 23, 2025
BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.
Via Stocktwits · May 23, 2025
Via Benzinga · May 23, 2025

Merus announced a research collaboration and license agreement with Biohaven.
Via Benzinga · January 13, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · May 23, 2025
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
Via Investor's Business Daily · May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · May 23, 2025
- 63% response rate observed among 43 evaluable patients
By Merus N.V. · Via GlobeNewswire · May 22, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), in the scientific journal “Cancers”, a MDPI publication, available here.
By Merus N.V. · Via GlobeNewswire · May 15, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET.
By Merus N.V. · Via GlobeNewswire · May 8, 2025
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting
By Merus N.V. · Via GlobeNewswire · May 7, 2025
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation
By Merus N.V. · Via GlobeNewswire · April 23, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.
By Merus N.V. · Via GlobeNewswire · April 1, 2025

- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25
By Merus N.V. · Via GlobeNewswire · February 27, 2025

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
By Merus N.V. · Via GlobeNewswire · February 25, 2025

Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for petosemtamab in combination with pembrolizumab.
Via Benzinga · February 18, 2025

This marks the second BTD for petosemtamab in HNSCC
By Merus N.V. · Via GlobeNewswire · February 18, 2025

Via Benzinga · February 13, 2025

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET.
By Merus N.V. · Via GlobeNewswire · February 13, 2025

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial for Bizengri® (zenocutuzumab), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.
By Merus N.V. · Via GlobeNewswire · February 5, 2025

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus’ leading Biclonics® technology platform, and Biohaven’s next-generation ADC conjugation and payload platform technologies.
By Merus N.V. · Via GlobeNewswire · January 12, 2025

Via Benzinga · January 10, 2025

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the first patient has been dosed in the Company’s phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics® targeting EGFR and LGR5.
By Merus N.V. · Via GlobeNewswire · December 16, 2024

Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025
By Merus N.V. · Via GlobeNewswire · December 7, 2024